A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment
Description
Phase
N/AInclusion and Exclusion Criteria
- Diagnosis of non-infectious intermediate, posterior, or pan
- uveitis in at least one eye
- Controlled uveitic disease in both eyes
- Stable dose of oral corticosteroids in combination with selected stable immunosuppressive therapy
- Effective contraceptive measures
- Infectious uveitis and masquerade syndromes
- Isolated anterior uveitis
- Contraindication to mydriatics
- Active tuberculosis disease
- History of allergic or anaphylactic reactions to monoclonal antibodies
- History of recurrent infection or predisposition to infection; active ocular infection
- Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply
Sites
Please contact Yoon Hee Kim to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI